Skip to main content

autologous anti-cd19 car-t cells caba-201

Generic: Autologous Anti-CD19 CAR-T Cells CABA-201

autologous anti-cd19 car-t cells caba-201: sourced relationships with 1 company · 5 clinical trials tracked.

autologous anti-cd19 car-t cells caba-201 evidence translation

What we can confirm

What it means

Source-backed records connect autologous anti-cd19 car-t cells caba-201 to CABA; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could autologous anti-cd19 car-t cells caba-201 → CABA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence7 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Cabaletta Bio, Inc. (CABA)
developer · Reported 2024-03-21 · Current development: unknownSource
Systemic Sclerosis; Relapsing Multiple Sclerosis (RMS); Pemp…
Phase 2/Phase 3
Clinical Trial Registry Records (5)

RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis

NCT07006805Registry updated 2026-06-25·Phase 1/Phase 2·CABA
Withdrawn

Primary endpoint: Primary (Part A: Dose Escalation) incidence and severity of adverse events

Interventionalopen0 enrolledStarted 2026-06Completion 2029-10Cabaletta Bio

RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis

NCT06359041Registry updated 2026-08-13·Phase 1/Phase 2·CABA
Recruiting

Primary endpoint: To evaluate incidence and severity of adverse events (AEs)

Interventionalopen24 targetStarted 2024-12Completion 2029-0917 sites · United StatesCabaletta Bio

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis

NCT06328777Registry updated 2026-08-17·Phase 2/Phase 3·CABA
Recruiting

Primary endpoint: Phase 1/2: To evaluate incidence of adverse events

Interventionalopen37 targetStarted 2024-07Completion 2029-0710 sites · United StatesCabaletta Bio

A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus

NCT06121297Registry updated 2026-10-06·Phase 1/Phase 2·CABA
Recruiting

Primary endpoint: To evaluate incidence of adverse events

Interventionalopen28 targetStarted 2024-02Completion 2029-1223 sites · Canada, Spain, United StatesCabaletta Bio

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

NCT04422912Registry updated 2026-05-29·Phase 1/Phase 2·CABA
Recruiting

Primary endpoint: Adverse events, including Dose Limit Toxicity

Interventionalopen40 targetStarted 2020-09Completion 2029-0113 sites · United StatesCabaletta Bio

Frequently asked questions

Which companies have sourced relationships with autologous anti-cd19 car-t cells caba-201?

autologous anti-cd19 car-t cells caba-201 has dated SEC/FDA relationship records for Cabaletta Bio, Inc..

How many clinical trials involve autologous anti-cd19 car-t cells caba-201?

BioSniper tracks 5 clinical trials involving autologous anti-cd19 car-t cells caba-201.